Targeting Fas in osteoresorptive disorders

Bibliography

• French LE, Hahne M, Viard I, Fas and Fas ligand in embryos and adult mice: ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover. J Cell Biol 1996;133(2):335-43
   PubMed Web of Science ®Google Scholar
• Guicciardi ME, Gores GJ. Life and death by death receptors. FASEB J 2009;23(6):1625-37
   PubMed Web of Science ®Google Scholar
• Sharma K, Wang RX, Zhang LY, Death the Fas way: regulation and pathophysiology of CD95 and its ligand. Pharmacol Ther 2000;88(3):333-47
   PubMed Web of Science ®Google Scholar
• Itoh N, Nagata S. A novel protein domain required for apoptosis. Mutational analysis of human Fas antigen. J Biol Chem 1993;268(15):10932-7
   PubMed Web of Science ®Google Scholar
• Cheng J, Zhou T, Liu C, Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 1994;263(5154):1759-62
   PubMed Web of Science ®Google Scholar
• Aggarwal BB. Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 2003;3(9):745-56
   PubMed Web of Science ®Google Scholar
• Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993;75(6):1169-78
   PubMed Web of Science ®Google Scholar
• Barry M, Bleackley RC. Cytotoxic T lymphocytes: all roads lead to death. Nat Rev Immunol 2002;2(6):401-9
   PubMed Web of Science ®Google Scholar
• Griffith TS, Brunner T, Fletcher SM, Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995;270(5239):1189-92
   PubMed Web of Science ®Google Scholar
• Hohlbaum AM, Moe S, Marshak-Rothstein A. Opposing effects of transmembrane and soluble Fas ligand expression on inflammation and tumor cell survival. J Exp Med 2000;191(7):1209-20
   PubMed Web of Science ®Google Scholar
• Ramaswamy M, Cleland SY, Cruz AC, Siegel RM. Many checkpoints on the road to cell death: regulation of Fas-FasL interactions and Fas signaling in peripheral immune responses. Results Probl Cell Differ 2009;49:17-47
   PubMedGoogle Scholar
• Yu KY, Kwon B, Ni J, A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses LIGHT-mediated apoptosis. J Biol Chem 1999;274(20):13733-6
   PubMed Web of Science ®Google Scholar
• Sun M, Ames KT, Suzuki I, Fink PJ. The cytoplasmic domain of Fas ligand costimulates TCR signals. J Immunol 2006;177(3):1481-91
   PubMed Web of Science ®Google Scholar
• Sancho-Martinez I, Martin-Villalba A. Tyrosine phosphorylation and CD95: a FAScinating switch. Cell Cycle 2009;8(6):838-42
   PubMed Web of Science ®Google Scholar
• Dempsey PW, Doyle SE, He JQ, Cheng G. The signaling adaptors and pathways activated by TNF superfamily. Cytokine Growth Factor Rev 2003;14(3-4):193-209
   PubMed Web of Science ®Google Scholar
• Strasser A, Jost PJ, Nagata S. The many roles of FAS receptor signaling in the immune system. Immunity 2009;30(2):180-92
   PubMed Web of Science ®Google Scholar
• Lavrik I, Golks A, Krammer PH. Death receptor signaling. J Cell Sci 2005;118(Pt 2):265-7
   PubMed Web of Science ®Google Scholar
• Mahmood Z, Shukla Y. Death receptors: targets for cancer therapy. Exp Cell Res 2010;316(6):887-99
   PubMed Web of Science ®Google Scholar
• Pallasch CP, Wendtner CM. Overexpression of the Fas-inhibitory molecule TOSO: a novel antiapoptotic factor in chronic lymphocytic leukemia. Leuk Lymphoma 2009;50(3):498-501
   PubMed Web of Science ®Google Scholar
• Muppidi JR, Tschopp J, Siegel RM. Life and death decisions: secondary complexes and lipid rafts in TNF receptor family signal transduction. Immunity 2004;21(4):461-5
   PubMed Web of Science ®Google Scholar
• Hamad AR. Analysis of gene profile, steady state proliferation and apoptosis of double-negative T cells in the periphery and gut epithelium provides new insights into the biological functions of the Fas pathway. Immunol Res 2010;47(1-3):134-42
   PubMed Web of Science ®Google Scholar
• Dhein J, Walczak H, Baumler C, Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature 1995;373(6513):438-41
   PubMed Web of Science ®Google Scholar
• Ingulli E, Mondino A, Khoruts A, Jenkins MK. In vivo detection of dendritic cell antigen presentation to CD4(+) T cells. J Exp Med 1997;185(12):2133-41
   PubMed Web of Science ®Google Scholar
• Villena SN, Pinheiro RO, Pinheiro CS, Capsular polysaccharides galactoxylomannan and glucuronoxylomannan from Cryptococcus neoformans induce macrophage apoptosis mediated by Fas ligand. Cell Microbiol 2008;10(6):1274-85
   PubMed Web of Science ®Google Scholar
• Krammer PH. CD95′s deadly mission in the immune system. Nature 2000;407(6805):789-95
   PubMed Web of Science ®Google Scholar
• Mori T, Ando K, Tanaka K, Fas-mediated apoptosis of the hematopoietic progenitor cells in mice infected with murine cytomegalovirus. Blood 1997;89(10):3565-73
   PubMed Web of Science ®Google Scholar
• Screpanti V, Wallin RP, Grandien A, Ljunggren HG. Impact of FASL-induced apoptosis in the elimination of tumor cells by NK cells. Mol Immunol 2005;42(4):495-9
   PubMed Web of Science ®Google Scholar
• Gorbachev AV, Fairchild RL. CD4+ T cells regulate CD8+ T cell-mediated cutaneous immune responses by restricting effector T cell development through a Fas ligand-dependent mechanism. J Immunol 2004;172(4):2286-95
   PubMed Web of Science ®Google Scholar
• Giroux M, Denis F. CD1d-unrestricted human NKT cells release chemokines upon Fas engagement. Blood 2005;105(2):703-10
   PubMed Web of Science ®Google Scholar
• Rescigno M, Piguet V, Valzasina B, Fas engagement induces the maturation of dendritic cells (DCs), the release of interleukin (IL)-1beta, and the production of interferon gamma in the absence of IL-12 during DC-T cell cognate interaction: a new role for Fas ligand in inflammatory responses. J Exp Med 2000;192(11):1661-8
   PubMed Web of Science ®Google Scholar
• Josefsen D, Myklebust JH, Lynch DH, Fas ligand promotes cell survival of immature human bone marrow CD34+CD38- hematopoietic progenitor cells by suppressing apoptosis. Exp Hematol 1999;27(9):1451-9
   PubMed Web of Science ®Google Scholar
• Barcena A, Muench MO, Song KS, Role of CD95/Fas and its ligand in the regulation of the growth of human CD34(++)CD38(-) fetal liver cells. Exp Hematol 1999;27(9):1428-39
   PubMed Web of Science ®Google Scholar
• Kleber S, Sancho-Martinez I, Wiestler B, Yes and PI3K bind CD95 to signal invasion of glioblastoma. Cancer Cell 2008;13(3):235-48
   PubMed Web of Science ®Google Scholar
• Barnhart BC, Legembre P, Pietras E, CD95 ligand induces motility and invasiveness of apoptosis-resistant tumor cells. EMBO J 2004;23(15):3175-85
   PubMed Web of Science ®Google Scholar
• Neumann L, Pforr C, Beaudouin J, Dynamics within the CD95 death-inducing signaling complex decide life and death of cells. Mol Syst Biol 2010;6:352
   Google Scholar
• Frelin C, Imbert V, Bottero V, Inhibition of the NF-kappaB survival pathway via caspase-dependent cleavage of the IKK complex scaffold protein and NF-kappaB essential modulator NEMO. Cell Death Differ 2008;15(1):152-60
   PubMed Web of Science ®Google Scholar
• Desbarats J, Birge RB, Mimouni-Rongy M, Fas engagement induces neurite growth through ERK activation and p35 upregulation. Nat Cell Biol 2003;5(2):118-25
   PubMed Web of Science ®Google Scholar
• Tourian L Jr, Zhao H, Srikant CB. p38alpha, but not p38beta, inhibits the phosphorylation and presence of c-FLIPS in DISC to potentiate Fas-mediated caspase-8 activation and type I apoptotic signaling. J Cell Sci 2004;117(Pt 26):6459-71
   PubMed Web of Science ®Google Scholar
• Djouad F, Jackson WM, Bobick BE, Activin A expression regulates multipotency of mesenchymal progenitor cells. Stem Cell Res Ther 2010;1(2):11
   PubMedGoogle Scholar
• Grcevic D, Lukic IK, Kovacic N, Activated T lymphocytes suppress osteoclastogenesis by diverting early monocyte/macrophage progenitor lineage commitment towards dendritic cell differentiation through down-regulation of receptor activator of nuclear factor-kappaB and c-Fos. Clin Exp Immunol 2006;146(1):146-58
   PubMed Web of Science ®Google Scholar
• Bu R, Borysenko CW, Li Y, Expression and function of TNF-family proteins and receptors in human osteoblasts. Bone 2003;33(5):760-70
   PubMed Web of Science ®Google Scholar
• Lepri E, Delfino DV, Migliorati G, Functional expression of Fas on mouse bone marrow stromal cells: upregulation by tumor necrosis factor-alpha and interferon-gamma. Exp Hematol 1998;26(13):1202-8
   PubMed Web of Science ®Google Scholar
• Wu X, McKenna MA, Feng X, Osteoclast apoptosis: the role of Fas in vivo and in vitro. Endocrinology 2003;144(12):5545-55
   PubMed Web of Science ®Google Scholar
• Qiao C, Xu W, Zhu W, Human mesenchymal stem cells isolated from the umbilical cord. Cell Biol Int 2008;32(1):8-15
   PubMed Web of Science ®Google Scholar
• Wieczorek G, Steinhoff C, Schulz R, Gene expression profile of mouse bone marrow stromal cells determined by cDNA microarray analysis. Cell Tissue Res 2003;311(2):227-37
   PubMed Web of Science ®Google Scholar
• Kawakami A, Eguchi K, Matsuoka N, Fas and Fas ligand interaction is necessary for human osteoblast apoptosis. J Bone Miner Res 1997;12(10):1637-46
   PubMed Web of Science ®Google Scholar
• Ozeki N, Mogi M, Nakamura H, Togari A. Differential expression of the Fas-Fas ligand system on cytokine-induced apoptotic cell death in mouse osteoblastic cells. Arch Oral Biol 2002;47(7):511-17
   PubMed Web of Science ®Google Scholar
• Kovacic N, Lukic IK, Grcevic D, The Fas/Fas ligand system inhibits differentiation of murine osteoblasts but has a limited role in osteoblast and osteoclast apoptosis. J Immunol 2007;178(6):3379-89
   PubMed Web of Science ®Google Scholar
• Kawakami A, Nakashima T, Tsuboi M, Insulin-like growth factor I stimulates proliferation and Fas-mediated apoptosis of human osteoblasts. Biochem Biophys Res Commun 1998;247(1):46-51
   PubMed Web of Science ®Google Scholar
• Duque G, El Abdaimi K, Henderson JE, Vitamin D inhibits Fas ligand-induced apoptosis in human osteoblasts by regulating components of both the mitochondrial and Fas-related pathways. Bone 2004;35(1):57-64
   PubMed Web of Science ®Google Scholar
• Jilka RL, Weinstein RS, Bellido T, Osteoblast programmed cell death (apoptosis): modulation by growth factors and cytokines. J Bone Miner Res 1998;13(5):793-802
   PubMed Web of Science ®Google Scholar
• Roux S, Lambert-Comeau P, Saint-Pierre C, Death receptors, Fas and TRAIL receptors, are involved in human osteoclast apoptosis. Biochem Biophys Res Commun 2005;333(1):42-50
   PubMed Web of Science ®Google Scholar
• Ogawa Y, Ohtsuki M, Uzuki M, Suppression of osteoclastogenesis in rheumatoid arthritis by induction of apoptosis in activated CD4+ T cells. Arthritis Rheum 2003;48(12):3350-8
   PubMedGoogle Scholar
• Park H, Jung YK, Park OJ, Interaction of Fas ligand and Fas expressed on osteoclast precursors increases osteoclastogenesis. J Immunol 2005;175(11):7193-201
   PubMed Web of Science ®Google Scholar
• Nakamura T, Imai Y, Matsumoto T, Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts. Cell 2007;130(5):811-23
   PubMed Web of Science ®Google Scholar
• Wu X, Pan G, McKenna MA, RANKL regulates Fas expression and Fas-mediated apoptosis in osteoclasts. J Bone Miner Res 2005;20(1):107-16
   PubMed Web of Science ®Google Scholar
• Krum SA, Miranda-Carboni GA, Hauschka PV, Estrogen protects bone by inducing Fas ligand in osteoblasts to regulate osteoclast survival. EMBO J 2008;27(3):535-45
   PubMed Web of Science ®Google Scholar
• Kitaura H, Nagata N, Fujimura Y, Effect of IL-12 on TNF-alpha-mediated osteoclast formation in bone marrow cells: apoptosis mediated by Fas/Fas ligand interaction. J Immunol 2002;169(9):4732-8
   PubMed Web of Science ®Google Scholar
• Yoshimatsu M, Kitaura H, Fujimura Y, IL-12 inhibits TNF-alpha induced osteoclastogenesis via a T cell-independent mechanism in vivo. Bone 2009;45(5):1010-16
   PubMed Web of Science ®Google Scholar
• Takahashi T, Tanaka M, Brannan CI, Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 1994;76(6):969-76
   PubMed Web of Science ®Google Scholar
• Roths JB, Murphy ED, Eicher EM. A new mutation, gld, that produces lymphoproliferation and autoimmunity in C3H/HeJ mice. J Exp Med 1984;159(1):1-20
   PubMed Web of Science ®Google Scholar
• Ramsdell F, Seaman MS, Miller RE, gld/gld mice are unable to express a functional ligand for Fas. Eur J Immunol 1994;24(4):928-33
   PubMed Web of Science ®Google Scholar
• Watanabe-Fukunaga R, Brannan CI, Itoh N, The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen. J Immunol 1992;148(4):1274-9
   PubMed Web of Science ®Google Scholar
• Murphy ED, Roths JB. Lymphoproliferation (lpr). Mouse News Lett 1978;58:47
   Google Scholar
• Allen RD, Marshall JD, Roths JB, Sidman CL. Differences defined by bone marrow transplantation suggest that lpr and gld are mutations of genes encoding an interacting pair of molecules. J Exp Med 1990;172(5):1367-75
   PubMed Web of Science ®Google Scholar
• Mariani SM, Matiba B, Armandola EA, Krammer PH. The APO-1/Fas (CD95) receptor is expressed in homozygous MRL/lpr mice. Eur J Immunol 1994;24(12):3119-23
   PubMed Web of Science ®Google Scholar
• Hahne M, Peitsch MC, Irmler M, Characterization of the non-functional Fas ligand of gld mice. Int Immunol 1995;7(9):1381-6
   PubMed Web of Science ®Google Scholar
• Adachi M, Suematsu S, Kondo T, Targeted mutation in the Fas gene causes hyperplasia in peripheral lymphoid organs and liver. Nat Genet 1995;11(3):294-300
   PubMed Web of Science ®Google Scholar
• Karray S, Kress C, Cuvellier S, Complete loss of Fas ligand gene causes massive lymphoproliferation and early death, indicating a residual activity of gld allele. J Immunol 2004;172(4):2118-25
   PubMed Web of Science ®Google Scholar
• Hughes DE, Boyce BF. Apoptosis in bone physiology and disease. Mol Pathol 1997;50(3):132-7
   PubMedGoogle Scholar
• Kincade PW, Medina KL, Smithson G. Sex hormones as negative regulators of lymphopoiesis. Immunol Rev 1994;137:119-34
   PubMed Web of Science ®Google Scholar
• Jilka RL, Hangoc G, Girasole G, Increased osteoclast development after estrogen loss: mediation by interleukin-6. Science 1992;257(5066):88-91
   PubMed Web of Science ®Google Scholar
• Imai Y, Youn MY, Kondoh S, Estrogens maintain bone mass by regulating expression of genes controlling function and life span in mature osteoclasts. Ann NY Acad Sci 2009;1173(Suppl 1):E31-9
   Google Scholar
• Katavic V, Lukic IK, Kovacic N, Increased bone mass is a part of the generalized lymphoproliferative disorder phenotype in the mouse. J Immunol 2003;170(3):1540-7
   PubMed Web of Science ®Google Scholar
• Kovacic N, Grcevic D, Katavic V, Fas receptor is required for estrogen deficiency-induced bone loss in mice. Lab Invest 2010;90(3):402-13
   PubMed Web of Science ®Google Scholar
• Goronzy JJ, Weyand CM. Developments in the scientific understanding of rheumatoid arthritis. Arthritis Res Ther 2009;11(5):249
   PubMed Web of Science ®Google Scholar
• Li X, Makarov SS. An essential role of NF-kappaB in the “tumor-like” phenotype of arthritic synoviocytes. Proc Natl Acad Sci USA 2006;103(46):17432-7
   PubMed Web of Science ®Google Scholar
• Ratkay LG, Zhang L, Tonzetich J, Waterfield JD. Complete Freund's adjuvant induces an earlier and more severe arthritis in MRL-lpr mice. J Immunol 1993;151(9):5081-7
   PubMed Web of Science ®Google Scholar
• Hoang TR, Hammermuller A, Mix E, A proinflammatory role for Fas in joints of mice with collagen-induced arthritis. Arthritis Res Ther 2004;6(5):R404-14
   Web of Science ®Google Scholar
• Straus SE, Sneller M, Lenardo MJ, An inherited disorder of lymphocyte apoptosis: the autoimmune lymphoproliferative syndrome. Ann Intern Med 1999;130(7):591-601
   PubMed Web of Science ®Google Scholar
• Siegel RM, Chan FK, Chun HJ, Lenardo MJ. The multifaceted role of Fas signaling in immune cell homeostasis and autoimmunity. Nat Immunol 2000;1(6):469-74
   PubMed Web of Science ®Google Scholar
• Eguchi K. Apoptosis in autoimmune diseases. Intern Med 2001;40(4):275-84
   PubMed Web of Science ®Google Scholar
• French LE, Tschopp J. Inhibition of death receptor signaling by FLICE-inhibitory protein as a mechanism for immune escape of tumors. J Exp Med 1999;190(7):891-4
   PubMed Web of Science ®Google Scholar
• Scholz M, Cinatl J. Fas/FasL interaction: a novel immune therapy approach with immobilized biologicals. Med Res Rev 2005;25(3):331-42
   PubMed Web of Science ®Google Scholar
• Sipos W, Pietschmann P, Rauner M. Strategies for novel therapeutic approaches targeting cytokines and signaling pathways of osteoclasto- and osteoblastogenesis in the fight against immune-mediated bone and joint diseases. Curr Med Chem 2008;15(2):127-36
   PubMed Web of Science ®Google Scholar
• Raisz LG. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest 2005;115(12):3318-25
   PubMed Web of Science ®Google Scholar
• Weitzmann MN, Pacifici R. T cells: unexpected players in the bone loss induced by estrogen deficiency and in basal bone homeostasis. Ann NY Acad Sci 2007;1116:360-75
   PubMed Web of Science ®Google Scholar
• Garcia-Moreno C, Catalan MP, Ortiz A, Modulation of survival in osteoblasts from postmenopausal women. Bone 2004;35(1):170-7
   PubMed Web of Science ®Google Scholar
• Yamaza T, Miura Y, Bi Y, Pharmacologic stem cell based intervention as a new approach to osteoporosis treatment in rodents. PLoS One 2008;3(7):e2615
   Web of Science ®Google Scholar
• Peng SL. Fas (CD95)-related apoptosis and rheumatoid arthritis. Rheumatology (Oxford) 2006;45(1):26-30
   PubMed Web of Science ®Google Scholar
• Du F, Wang L, Zhang Y, Role of GADD45 beta in the regulation of synovial fluid T cell apoptosis in rheumatoid arthritis. Clin Immunol 2008;128(2):238-47
   PubMed Web of Science ®Google Scholar
• Szodoray P, Jellestad S, Nakken B, Programmed cell death in rheumatoid arthritis peripheral blood T-cell subpopulations determined by laser scanning cytometry. Lab Invest 2003;83(12):1839-48
   PubMed Web of Science ®Google Scholar
• Grcevic D, Jajic Z, Kovacic N, Peripheral blood expression profiles of bone morphogenetic proteins, tumor necrosis factor-superfamily molecules, and transcription factor Runx2 could be used as markers of the form of arthritis, disease activity, and therapeutic responsiveness. J Rheumatol 2010;37(2):246-56
   PubMed Web of Science ®Google Scholar
• Telegina E, Reshetnyak T, Moshnikova A, A possible role of Fas-ligand-mediated “reverse signaling” in pathogenesis of rheumatoid arthritis and systemic lupus erythematosus. Immunol Lett 2009;122(1):12-7
   PubMed Web of Science ®Google Scholar
• Smith MD, Walker JG. Apoptosis a relevant therapeutic target in rheumatoid arthritis? Rheumatology (Oxford) 2004;43(4):405-7
   PubMed Web of Science ®Google Scholar
• Hagimoto N, Kuwano K, Miyazaki H, Induction of apoptosis and pulmonary fibrosis in mice in response to ligation of Fas antigen. Am J Respir Cell Mol Biol 1997;17(3):272-8
   PubMed Web of Science ®Google Scholar
• Ogasawara J, Watanabe-Fukunaga R, Adachi M, Lethal effect of the anti-Fas antibody in mice. Nature 1993;364(6440):806-9
   PubMed Web of Science ®Google Scholar
• Carbone LD, Tylavsky FA, Cauley JA, Association between bone mineral density and the use of nonsteroidal anti-inflammatory drugs and aspirin: impact of cyclooxygenase selectivity. J Bone Miner Res 2003;18(10):1795-802
   PubMed Web of Science ®Google Scholar
• Catrina AI, Trollmo C, af Klint E, Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report. Arthritis Rheum 2005;52(1):61-72
   PubMedGoogle Scholar
• Ohshima S, Mima T, Sasai M, Tumour necrosis factor alpha (TNF-alpha) interferes with Fas-mediated apoptotic cell death on rheumatoid arthritis (RA) synovial cells: a possible mechanism of rheumatoid synovial hyperplasia and a clinical benefit of anti-TNF-alpha therapy for RA. Cytokine 2000;12(3):281-8
   PubMed Web of Science ®Google Scholar
• Wessels JA, Huizinga TW, Guchelaar HJ. Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2008;47(3):249-55
   PubMed Web of Science ®Google Scholar
• ElOjeimy S, McKillop JC, El-Zawahry AM, FasL gene therapy: a new therapeutic modality for head and neck cancer. Cancer Gene Ther 2006;13(8):739-45
   PubMed Web of Science ®Google Scholar
• Wesche-Soldato DE, Swan RZ, Chung CS, Ayala A. The apoptotic pathway as a therapeutic target in sepsis. Curr Drug Targets 2007;8(4):493-500
   PubMed Web of Science ®Google Scholar
• de Vries EG, Timmer T, Mulder NH, Modulation of death receptor pathways in oncology. Drugs Today (Barc) 2003;39(Suppl C):95-109
   PubMedGoogle Scholar
• Mocellin S. Targeting death receptors to fight cancer: from biological rational to clinical implementation. Curr Med Chem 2010;17(25):2713-28
   PubMed Web of Science ®Google Scholar
• Garcia S, Liz M, Gomez-Reino JJ, Conde C. Akt activity protects rheumatoid synovial fibroblasts from Fas-induced apoptosis by inhibition of Bid cleavage. Arthritis Res Ther 2010;12(1):R33
   Web of Science ®Google Scholar
• Ducy P, Zhang R, Geoffroy V, Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell 1997;89(5):747-54
   PubMed Web of Science ®Google Scholar
• Lavrik IN, Golks A, Krammer PH. Caspases: pharmacological manipulation of cell death. J Clin Invest 2005;115(10):2665-72
   PubMed Web of Science ®Google Scholar
• Miura M, Chen XD, Allen MR, A crucial role of caspase-3 in osteogenic differentiation of bone marrow stromal stem cells. J Clin Invest 2004;114(12):1704-13
   PubMed Web of Science ®Google Scholar
• Takayanagi H. Mechanistic insight into osteoclast differentiation in osteoimmunology. J Mol Med 2005;83(3):170-9
   PubMed Web of Science ®Google Scholar
• Williams JP, Micoli K, McDonald JM. Calmodulin-an often-ignored signal in osteoclasts. Ann NY Acad Sci 2010;1192(1):358-64
   PubMedGoogle Scholar
• Choi HJ, Park YR, Nepal M, Inhibition of osteoclastogenic differentiation by Ikarisoside A in RAW 264.7 cells via JNK and NF-kappaB signaling pathways. Eur J Pharmacol 2010;636(1-3):28-35
   PubMed Web of Science ®Google Scholar